https://www.selleckchem.com/products/ABT-888.html
The abovementioned efficacies between these two eye drops were not statistically significant. However, the number of scratching and wiping behaviors in the MZR-treated group was significantly less than in the Restasis-treated group. MZR (0.05% in PBS) could be a good competitive product for Restasis because of the comparable treatment effect in dry eye diseases and better ocular tolerability in ocular itch and pain. This study provided an immunosuppressive agent comparable to Restasis for the treatment of dry eye disease. This study pro
Gefällt mir
Kommentar
Teilen
